Evolution of the gross tumour volume extent during radiotherapy for glioblastomas.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
07 2021
Historique:
received: 16 10 2020
revised: 05 03 2021
accepted: 06 04 2021
pubmed: 14 4 2021
medline: 28 7 2021
entrez: 13 4 2021
Statut: ppublish

Résumé

Tumour growth during radiotherapy may lead to geographical misses of the target volume. This study investigates the evolution of the tumour extent and evaluates the need for plan adaptation to ensure dose coverage of the target in glioblastoma patients. The prospective study included 29 patients referred for 59.4 Gy in 33 fractions. Magnetic resonance imaging (MRI) was performed at the time of treatment planning, at fraction 10, 20, 30, and three weeks after the end of radiotherapy. The gross tumour volume (GTV) was defined as the T1w contrast-enhanced region plus the surgical cavity on each MRI set. The relative GTV volume and the maximum distance (D Dose coverage of the GTV during radiotherapy was not compromised, and none of the radiotherapy plans was adapted. The median D Large variations in the GTV extent were observed, and changes often occurred early in the treatment. Plan adaptation for geographical misses was not performed in our cohort due to sufficient CTV margins.

Sections du résumé

BACKGROUND AND PURPOSE
Tumour growth during radiotherapy may lead to geographical misses of the target volume. This study investigates the evolution of the tumour extent and evaluates the need for plan adaptation to ensure dose coverage of the target in glioblastoma patients.
MATERIALS AND METHODS
The prospective study included 29 patients referred for 59.4 Gy in 33 fractions. Magnetic resonance imaging (MRI) was performed at the time of treatment planning, at fraction 10, 20, 30, and three weeks after the end of radiotherapy. The gross tumour volume (GTV) was defined as the T1w contrast-enhanced region plus the surgical cavity on each MRI set. The relative GTV volume and the maximum distance (D
RESULTS
Dose coverage of the GTV during radiotherapy was not compromised, and none of the radiotherapy plans was adapted. The median D
CONCLUSION
Large variations in the GTV extent were observed, and changes often occurred early in the treatment. Plan adaptation for geographical misses was not performed in our cohort due to sufficient CTV margins.

Identifiants

pubmed: 33848564
pii: S0167-8140(21)06182-X
doi: 10.1016/j.radonc.2021.04.001
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

40-46

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Uffe Bernchou (U)

Laboratory of Radiation Physics, Department of Oncology, Odense University Hospital, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Electronic address: uffe.bernchou@rsyd.dk.

Trine Skak Tranemose Arnold (TST)

Department of Oncology, Odense University Hospital, Denmark.

Brit Axelsen (B)

Laboratory of Radiation Physics, Department of Oncology, Odense University Hospital, Denmark.

Mette Klüver-Kristensen (M)

Laboratory of Radiation Physics, Department of Oncology, Odense University Hospital, Denmark.

Faisal Mahmood (F)

Laboratory of Radiation Physics, Department of Oncology, Odense University Hospital, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Frederik Severin Gråe Harbo (FSG)

Department of Radiology, Odense University Hospital, Denmark.

Jon Thor Asmussen (JT)

Department of Radiology, Odense University Hospital, Denmark.

Olfred Hansen (O)

Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Oncology, Odense University Hospital, Denmark.

Anders Smedegaard Bertelsen (AS)

Laboratory of Radiation Physics, Department of Oncology, Odense University Hospital, Denmark.

Steinbjørn Hansen (S)

Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Oncology, Odense University Hospital, Denmark.

Carsten Brink (C)

Laboratory of Radiation Physics, Department of Oncology, Odense University Hospital, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Rikke Hedegaard Dahlrot (RH)

Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Oncology, Odense University Hospital, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH